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Abstract 
The Smads are intracellular mediators of the signaling cascade initiated by the 
Transforming Growth Factor-Beta (TGF-β) superfamily of ligands.  Notable ligands include 
TGF-β, bone morphogenic proteins (BMPs), nodal, and activins.  These ligands affect a broad 
range of processes that including development, differentiation, homeostasis, and apoptosis.  One 
mechanism of ligand signal regulation involves dose-dependent nature of Smad transcriptional 
regulation.  Two distinct, although parallel, Smad pathways exist.  Smads 1, 5, and 8 mediate 
BMP signals while Smad2 and Smad3 mediate TGF-β, activin, and nodal signals.  Studies of 
Smad2 and Smad3 via knockout technologies reveal Smad3 functions in bone development and 
immune system function while Smad2 is required for gastrulation and proper development of 
anterior and midline structures.  Combinational studies using traditional Smad2 and Smad3 
knockout alleles uncovered a synergistic effect of Smad2 and Smad3 on liver development.  
Using a hypomorphic allele of Smad2, my studies of this interaction suggest that all 
abnormalities arising from insufficiencies of Smad2 and Smad3 mediation have been described, 
and that the abnormalities observed represent a continuum of abnormalities related to the amount 
of TGF-β-like signaling mediated by Smad2 and Smad3. 
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The ubiquitous Transforming Growth Factor-Beta (TGF-β) superfamily of ligands 
controls a myriad of processes that include cell differentiation, development, angiogenesis, 
immune system response, apoptosis, and homeostasis.  The most notable ligands of this 
superfamily are TGF-β, bone morphogenic proteins (BMPs), nodal, and activins [1],(reviewed in 
[2, 3]).  TGF-β ligands initiate the cell signaling pathway by binding to their respective 
transmembrane Type II receptor, which activates the serine/threonine kinase domain on the 
receptor.  This activated Type II receptor recruits a complimentary transmembrane Type I 
receptor and phosphorylates the glycine/serine rich domain of the Type I receptor to activate the 
Type I receptor’s own serine/threonine kinase.  The Type I serine/threonine kinase recognizes 
and phosphorylates a Serine Serine X Serine (SSXS) motif on the Mad homology 2 (MH2) 
domain of its respective receptor-activated Smad (R-Smads) (reviewed in [2, 3]).  These R-
Smads then form heteromeric complexes with the co-Smad (Smad4) en route to the nucleus 
where the complex will bind either with transcriptional coactivators such as p300 and induce 
transcription, or with transcriptional corepressors such as TGIF and repress transcription (Fig. 1). 
The Smad family of intracellular mediators is divided into three categories: R-Smads, co-
Smad, and inhibitory Smads (I-Smads).  The hallmark of the Smad proteins is the highly 
conserved N-terminal Mad homology 1 (MH1) and C-terminal MH2 domains, between which 
lies a more variable linker region [4] (Fig. 2).  The I-Smads—Smads 6 and 7—are the only 
Smads to lack the MH1 domain, but they possess intact SSXS motifs in their MH2 domains that 
allow one of their inhibitory mechanisms to operate by competitively inhibiting phosphorylation 
of R-Smads (reviewed in [2, 3]).  The bulk of research has been focused on R-Smads and Smad4, 
as their signaling directly leads to transcriptional responses.  R-Smads are made up of two 
 1
subfamilies.  Smads 1, 5, and 8 mediate BMP ligand signals while Smads 2 and 3 mediate 
signals from TGF-β, nodal, and activin.  R-Smad phosphorylation is dependent on binding to a 
specific combination of Type I and Type II receptor complexes (reviewed in [2, 3]).  Unlike the 
specificity of the receptor complexes, Smad4 binds to all activated R-Smads to form heteromeric 
complexes that translocate to the nucleus to regulate transcription. 
Interest in Smads has grown greatly following several reports implicating various Smads 
in tumorigenesis.  In fact, abnormalities in all Smads of the TGF-β/activin/nodal pathway have 
been reported in various tumors.  For instance, Smad4 is mutated in 50% of all pancreatic tumors 
[4, 5].  Smad2 expression is significantly reduced in head and neck carcinomas, while the gene 
itself is mutated in some lung and colorectal cancers (reviewed in [6])[7].  Finally, the loss of 
Smad3 is suspected of increasing susceptibility to human gastric cancer [8], while a study using 
the mouse model demonstrated that all Smad3 null mice develop metastatic colorectal cancer [9]. 
Knowing that a gene is abnormal in a tumor provides little information about the natural 
function of the gene though.  Understanding the natural function of the gene is important since 
such knowledge might assist the development of new therapies that will restore the normal 
function of mutated genes.  The most common approaches to ascertaining the natural function of 
a gene are through experiments in which the gene is manipulated to either overexpress or 
underexpress its encoded protein.  Most underexpression experiments take the form of gene 
knockouts to form null or hypomorphic alleles.  A mouse model is ideal for underexpression 
experiments in several respects including short maturity time, large litter sizes (eight to fifteen), 
similarity between human and mouse genomes, and the relative ease and accuracy with which 
knockouts can be performed and studied.  The nine distinct targeted disruptions of Smad2 
created since 1998 are a testament to how routine mice gene knockouts have become [10-18].  
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These knockouts have unveiled the importance of Smad2 during gastrulation, anterior/posterior 
axis determination, craniofacial development, and liver development.  Smad2 null mice fail to 
gastrulate, resulting in embryonic lethality around embryonic day 8.5 (E8.5).  About five percent 
of heterozygotes are abnormal, implying that the level of TGF-β signaling in heterozygotes is 
hovering barely above the threshold required for successful embryogenesis [10, 11].  Although 
highly homologous to Smad2 and a signal transducer for the same set of ligands, Smad3 does not 
appear to be vital for embryogenesis, as Smad3 null pups are viable.  Knockouts have uncovered 
the roles of Smad3 in immune system function, especially in the mucosal membranes, skeletal 
formation, and growth of ovarian follicles [9, 19, 20].  
Because Smad3 null mice do not exhibit embryonic lethality, the primary function of 
Smad3 was easily discerned for the entire lifespan of the mice.  However, the embryonic 
lethality of Smad2 leaves a gap of unknown function following the lethality by E8.5.  One of the 
initial approaches to fill in the void involved the combination of Smad2 with Smad3 mutations.  
Although Smad2 and Smad3 have distinct functions [20], they are both intracellular signal 
transducers for TGF-β/activin/nodal ligands.  Because Smad2 heterozygotes are already hovering 
around the minimum threshold of TGF-β signaling required for embryogenesis, any interaction 
between Smad2 and Smad3 should lower the level of TGF-β signaling below that threshold and 
result in abnormalities, uncovering insights into Smad2 function after E8.5.  The expected 
combination at which lethality might occur is Smad2+/-;Smad3-/- because individually, Smad2+/- 
mice and Smad3-/- mice are both viable.  However, a synergistic interaction between these two 
mediators was discovered when dissections revealed that Smad2+/-;Smad3+/- embryos do not 
survive past E16.5.  These embryos exhibited variably penetrant phenotypes including cardiac 
dysplasia, axial patterning defects, craniofacial abnormalities, and hepatic dysplasia.  This 
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experiment demonstrated that Smad2 and Smad3 cooperate during liver development, a function 
that was not discernable with individually Smad2-deficient or Smad3-deficient embryos [21, 22]. 
An alternative to combining mutations is to create conditional knockouts.  Courtesy of 
advances in knockout technology, investigators can now regulate knockouts spatiotemporally.  
Many conditional knockouts utilize the Cre-loxP system.  Cre is a bacteriophage recombinase 
with many functions, one function of which recognizes specific sequences of DNA called loxP 
sites, excises the genetic material between two successive loxP, and ligates the chromosome 
back together [23], (reviewed in [24]).  A conditional Smad2 allele was created using this Cre-
loxP system to study the role of Smad2 further in development [12].  A targeting construct was 
created with a loxP site inserted into intron 8 and a PGKneo cassette flanked by loxP sites 
inserted into intron 10 (Fig. 3).  Following electroporation of the targeting construct into ES cells 
and double selection for neomycin resistance in addition to lack of the gene for thymidine kinase, 
homologous recombination was screened for in DNA isolated from surviving cells by using a 5’ 
external probe.  Southern blot analysis confirmed the creation of the conditional Smad2 allele, 
called Smad23loxP.  After injection into a blastocyst and confirmation of transmission through the 
germline by PCR analysis, the Smad2 allele was crossed with a mouse carrying a Cre transgene 
that would be expressed in all embryonic tissues to generate recombined alleles (Fig. 4).  Genetic 
tests revealed that the resulting Smad2∆Ε9,10 allele behaved similarly to the Smad2- allele created 
by Nomura et al. and Weinstein et al. in 1998 [10, 11], and that the Smad2flox allele was 
indistinguishable from the wild-type allele, thus confirming the creation of a conditional null 
allele [12]. 
In addition to allowing spatiotemporal control of the knockout, an unexpected benefit of 
the Smad23loxP conditional allele was its hypomorphic behavior.  Although it was viable and 
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fertile in the homozygous state, 100% of Smad23loxP/- embryos exhibited embryonic lethality 
[12].  In contrast, only five percent of Smad2+/- embryos perished during embryogenesis [11].  
This hypomorphism was attributed to the presence of the neo cassette.  Many studies have 
demonstrated and taken advantage of the cryptic splice acceptor and donor sites within the neo 
cassette that cause part of the neo sequence to be incorporated into mRNA during transcription 
[12, 25, 26].  The location of the neo cassette in the Smad23loxP allele predicts a truncated, non-
functional protein translation when cryptic splicing occurs and neo is included in the mRNA 
transcript, as an in-frame stop codon within the neo cassette terminates translation before the 
SSXS motif required for Smad2 phosphorylation.  Other genetic experiments confirmed that the 




Although genetic experiments confirmed the hypomorphism of the Smad23loxP allele, the 
level of gene expression was left undetermined.  To visualize the Smad2 protein expression, 
Western blots were run on E10.5 embryo samples.  The epitope for Smad2 protein binds to the 
linker/MH2 region of Smad2, so the presence of Smad2 protein rather than functionality of 
Smad2 protein is detected.  As expected, the samples containing at least one allele of the 3loxP 
allele show reduced expression compared to wild-type (WT) samples (Fig. 5).  To quantitate the 
level of Smad2 mRNA, a real-time polymerase chain reaction (RT-PCR) was run on additional 
E10.5 embryo samples.  RT-PCR measures the amount of mRNA by recording the number of 
PCR cycles required to replicate enough cDNA to obtain a fluorescence signal from a sample.  
The RT-PCR primers amplify the region where neo cryptic splicing occurs, implying that only 
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functional mRNA transcripts are detected since primers would be too far separated for RT-PCR 
amplification when neo is cryptically spliced into mRNA.  RT-PCR results confirm the decrease 
in Smad2 expression by Western analysis since the Smad23loxP/− embryos expressed Smad2 
mRNA at about 30-40% the level of WT counterparts (data not shown).   
With the hypomorphism of Smad2 confirmed both in genetic and biochemical 
experiments, the allele was ready to be integrated into various projects investigating Smad2 
function.  One of these projects was the investigation of Smad2 and Smad3 interactions.  As 
mentioned earlier, most Smad2+/-;Smad3+/- embryos do not survive embryogenesis.  In this 
project the hypomorphic allele allows fine tuning of the Smad2 levels in contrast to the crude, 
50% increment limitations of the Smad2 null allele [21].  Tweaking the level of Smad2 
expression in smaller increments translates into the ability to adjust TGF-β signaling levels in 
smaller steps so that a more precise level of signaling required for successful embryogenesis can 
be uncovered. 
The new Smad2 hypomorphic allele created four new genotypic combinations of Smad2 
and Smad3 (Smad23loxP/+;Smad3+/-, Smad23loxP/+;Smad3-/-, Smad23loxP/3loxP;Smad3+/-, and 
Smad23loxP/3loxP;Smad3-/-), so crosses were arranged to determine the fates of animals carrying 
these new combinations (Fig. 6).  The initial cross between Smad23loxP/3loxP and Smad3+/- mice 
yielded normal pups with the expected genotypes at the expected Mendelian ratios (data not 
shown).  Smad23loxP/+;Smad3+/- mice were intercrossed, and Smad23loxP/+;Smad3-/- pups were 
born with the same phenotype as Smad3 null mice (data not shown).  However, no 
Smad23loxP/3loxP;Smad3-/- pups were observed in the F2 generation, so Smad23loxP/3loxP;Smad3+/- 
mice from the F2 generation were bred inter se to increase the expected frequency of 
Smad23loxP/3loxP;Smad3-/- pups.  At postnatal day twenty-one (the date of weaning), no 
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Smad23loxP/3loxP;Smad3-/- pups were observed, and chi-squared analysis produced a p value of 
<0.001 (Table 1), suggesting that the particular genotype exhibits embryonic lethality. 
Embryos from Smad23loxP/3loxP;Smad3+/- intercrosses were dissected to confirm 
embryonic lethality and to investigate the cause of embryonic lethality.  Embryos were first 
dissected between E9.5-E10.5 because embryos with axial patterning defects—the most severe 
Smad2+/-;Smad3+/- abnormality—survive to E10.5.  Expected ratios of embryo genotypes were 
recovered at E9.5 and E10.5; however, 100% of the Smad23loxP/3loxP;Smad3-/- embryos were 
abnormal.  Defects included cardiac dysplasia, axial patterning defects, holoprosencephaly 
(HPE), and delayed development (Table 2).  Seventy-five percent of the embryos were affected 
primarily by some form of cardiac dysplasia, either abnormal heart looping or pericardial 
effusion (Fig. 7B).  Furthermore, all E9.5-E10.5 Smad23loxP/3loxP;Smad3-/- embryos were smaller 
than wild-type littermates, and many exhibited craniofacial defects (Fig. 7C).  Interestingly, at 
the same stage of development, about thirty-five percent of Smad23loxP/3loxP;Smad3+/- embryos 
were abnormal (Table 2), though none of the defects were as severe as those seen in 
Smad23loxP/3loxP;Smad3-/- embryos (Fig. 7B,E).  None of the E9.5-E10.5 Smad23loxP/3loxP;Smad3+/- 
embryos exhibited axial patterning defects, but the embryos still displayed a variably penetrant 
phenotype including heart dysplasia, holoprosencephaly, and delayed development (Fig. 7F). 
Since hepatic dysplasia was an observed phenotype during studies of Smad2+/-;Smad3+/- 
embryos, and hepatic dysplasia cannot be discerned until E12.5-E14.5, dissections were 
performed between E12.5-E14.5 to determine whether any Smad23loxP/3loxP;Smad3-/- embryos 
would also succumb to liver abnormalities.  At this stage Smad23loxP/3loxP;Smad3-/- embryos were 
no longer observed at Mendelian ratios (Table 1), most likely because the embryos with the most 
severe axial patterning defects and cardiac dysplasia had already begun to resorb.  However, the 
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Smad23loxP/3loxP;Smad3-/- embryos that did survive to this stage were all abnormal, as all E12.5-
E14.5 Smad23loxP/3loxP;Smad3-/- embryos suffered from hepatic dysplasia (Fig. 8C,D), while fifty 
percent also suffered from varying degrees of anterior craniofacial defects including HPE (Fig. 
8A, C) and severe anterior truncation (Fig. 8B).  Of the forty-nine total Smad23loxP/3loxP;Smad3+/- 
embryos observed at this stage (Table 3), twenty-seven percent displayed abnormalities 
including severe anterior craniofacial truncation, hepatic dysplasia, and HPE.  Again, these 
phenotypes were not mutually exclusive, as three embryos with hepatic dysplasia were also 
afflicted with varying degrees of HPE. 
 
Discussion 
Levels of TGF-β signaling required for embryogenesis 
As previously mentioned, the five percent embryonic lethality of Smad2 heterozygotes 
suggests that losing fifty percent of functional Smad2 causes the embryos to hover close to the 
minimum threshold of TGF-β signaling required for viability (Fig. 9).  Smad2 null embryos 
transgress this threshold, and all embryos exhibit embryonic lethality [11].  Smad2/3 double 
heterozygotes also do not produce enough signaling to overcome this threshold, resulting in 
embryonic lethality, albeit at a later stage of development [21].  My investigations reveal that 
increasing levels of Smad2 marginally via the Smad23loxP/3loxP allele combination while keeping 
the level of Smad3 constant in the heterozygous state increases the viability of the embryos to 
approximately seventy percent.  However, replacing the Smad3+/- alleles with Smad3 null alleles 
decreases viability to 0%.  This data suggests that the Smad2 and Smad3 gene dosages appear to 
determine the severity of the resulting abnormality in a inversely proportional relationship, an 
observation supported by the Smad23loxP/3loxP;Smad3+/- embryo defects being less severe than 
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those of Smad23loxP/3loxP;Smad3-/- embryos.  In addition, the clear importance of Smad2 during 
development suggests that Smad2 acts as a coarse adjustment of TGF-β signaling levels while 
Smad3 acts as a fine tuner.  This observation was also noted by Dunn et al. in their studies of 
Smad2/3 interactions at an earlier stage (E6.5-9.5), although they quantitated their approximation 
of Smad2 contribution versus Smad3 contribution to total TGF-β signaling at each WT Smad2 
allele being worth two WT Smad3 alleles [27]. These new insights about the amount of Smad2 
and Smad3 required for embryogenesis viability are summarized in Table 4. 
  
Origin of variably penetrant phenotypes 
Variably penetrant phenotypes were observed with Smad2+/-;Smad3+/- , 
Smad23loxP/3loxP;Smad3+/-, Smad23loxP/3loxP;Smad3-/-, and Smad23loxP/- embryos.  Smad2/3 
combinations exhibit four classes of abnormalities including axial patterning defects, cardiac 
dysplasia, craniofacial defects, and hepatic dysplasia.  Smad23loxP/- embryo abnormalities are 
divided into three classes and, in general, manifest themselves at an earlier stage of development.  
The three classes are as follows: empty yolk sac, externalized embryo, and axial-patterning 
defect [12].  The cause of these distinct phenotypes within embryos of the same genotype is 
intriguing.  A potential source is the activity of strain-specific modifier genes.  Investigation into 
the Smad2/3 double heterozygotes also uncovered variably penetrant phenotypes.  However, 
when the strain background was switched from 129SvEv/NIH Black Swiss to A/J, Smad2+/-
;Smad3+/- pups were born alive with no visible abnormalities after one month [21].  Observations 
of Smad23loxP/3loxP;Smad3+/- and Smad23loxP/3loxP;Smad3-/- embryos support the presence of 
modifiers that adjust the severity of the observed phenotype.  For instance, at E9.5-E10.5, all 
Smad23loxP/3loxP;Smad3-/- embryos had severe axial defects or heart dysplasia that should have 
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resulted in resorptions by E13.5, but embryos were observed, though three of the four were from 
the same litter, suggesting that the embryos were may have expressed a unique combination of 
modifier genes that mitigated the usual effects of Smad2 and Smad3 depletion. 
 
A continuum of TGF-β signaling via Smad2 and Smad3 
The effects of Smad2 and Smad3 nullizygosity on embryogenesis have been investigated 
by many labs, resulting in many alleles that convey a broad spectrum of functional TGF-β 
signaling.  Smad3 mutations by themselves do not appear to vitally impact embryogenesis since 
null mice survive to parturition [19, 20].  Smad2, however, plays a fundamental role during 
embryogenesis, with Smad2 null embryos exhibiting gastrulation failures at E6.5 and resorbing 
by E8.5.  This was seen in the Smad2mh1, Smad2∆C, Smad2∆E9,10, and Hamamoto’s Smad2- alleles 
[10-13].  If the Smads transduce enough TGF-β signaling for the embryos to undergo 
gastrulation, the next threshold arises during anterior/posterior axis specification, as 
demonstrated by embryos homozygous for severely hypomorphic alleles of Smad2 such as 
Smad2Robm1, where exon one was replaced with a neo cassette; Smad2dex2, in which exon two was 
deleted with a neo cassette; and Smad2CD, in which exon one was flanked by loxP sites and 
excised via Cre-mediated recombination [14-16] (Fig. 10).  These alleles produce enough Smad2 
that TGF-β signaling requirements for gastrulation are met, and mesoderm is formed; however, 
all embryos homozygous for these alleles were abnormal with the phenotype of an empty yolk 
sac [14-16].  The empty yolk sac phenotype is also seen when the hypomorphic Smad2m1Mag 
allele was placed against the Smad2Robm1 allele.  The Smad2m1Mag allele was created with point 
mutation techniques to mutate serine-276 to leucine.  This serine is not, however, known to 
participate in any phosphorylation.  Regardless, the resulting conformation changes in Smad2 are 
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severe enough that Smad2m1Mag homozygotes are embryonically lethal, albeit enough TGF-β 
signaling is conveyed for homozygotes to progress further in development and form embryonic 
structures unlike the previously described alleles.  Smad2m1Mag/m1Mag embryos display a variably 
penetrant phenotype that include empty yolk sac, external embryo, and axial/heart defects with 
anterior truncation [17].  These are the three same phenotypes Smad23loxP/- embryos exhibit, 
though Smad23loxP homozygotes are viable and fertile [12].  What these two intermediately 
hypomorphic alleles suggest about TGF-β signaling is that another threshold of signaling occurs 
during anterior-posterior (A-P) axis specification, since development of embryos similar to 
Smad2Robm1 homozygotes arrested before A-P specification [14-16], while marker analysis of 
external embryos demonstrated A-P specification [21]. 
Combination of Smad2 alleles with Smad3 knockout alleles has yielded intriguing 
insights into TGF-β signaling mediated synergistically by Smad2 and Smad3 while also 
uncovering new thresholds.  Adding Smad3 mutations in embryos homozygous for the most 
severe hypomorphic allele, Smad2Robm1, results in a reduction of signaling that limits mesoderm 
formation [27].  Moving up the threshold ladder, Smad2Robm1/+;Smad3-/- embryos display a range 
of abnormalities including axial defects, anterior patterning defects [27], and pericardial 
effusions, all of which have been seen with the least severe class of Smad23loxP/- and 
Smad2m1Mag/m1Mag embryos [12, 17].  In addition, these abnormalities were also seen with the 
most severe class of Smad23loxP/3loxP;Smad3-/-, Smad23loxP/3loxP;Smad3+/-, and Smad2+/-;Smad3+/- 
embryos.  All of these observations suggest that these four allelic combinations overlap at a 
TGF-β signaling range that is sufficient for rudimentary anterior patterning, though not enough 
for embryogenesis to continue past E10.5.  In addition, these results support the synergism 
observation between Smad2 and Smad3 because the addition of Smad3 null mutations to 
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Smad23loxP/3loxP reduces signaling to an extent that abnormalities seen in the least severe, 
embryonically lethal Smad2 allele combinations are repeated. 
Focusing on embryos older than E7.5, the synergistic cooperation between Smad2 and 
Smad3 uncovers additional thresholds for TGF-β signaling.  After the embryos with severe 
axial/heart defects have resorbed by E11.5, embryos can still succumb to two abnormalities—
craniofacial defects and hepatic dysplasia.  Both of these appear dependent on the ligand Nodal.  
Studies of Nodal, a TGF-β-like ligand that signals via both Smad2 and Smad3, have elucidated 
its function in heart and anterior patterning [10, 27-30].   Nodal signaling contributes to proper 
heart patterning [29], so disruption of its signal transducers (Smad2 and Smad3) might lead to 
the aforementioned heart defects.  In addition, embryos heterozygous for Nodal mutations have 
displayed severe anterior truncations [10, 16, 29, 30], which was also seen in a fraction of 
Smad2mh1/+ embryos, [10] and in both Smad23loxP/3loxP;Smad3+/- and Smad23loxP/3loxP;Smad3-/- 
embryos.  Thus, an anterior patterning threshold exists after axis specification, a threshold at 
which deficiency results in craniofacial defects.   
The final threshold involves meeting the signal requirements for liver development.  
Interestingly, a fraction of Nodal mutants also display hepatic hypoplasia [30].  In addition, Liu 
et al. demonstrated that the Smad2+/-;Smad3+/- liver abnormalities were endodermal in origin 
[21].  Combining this with increasing evidence that both Smad2 and Smad3 mediate Nodal 
signals [27], a potential pathway and a possible threshold with its origin in the level of TGF-β 
signaling arises.  This pathway could be masked in mice harboring mutations in either Smad2 or 
Smad3 because enough Smad2 or Smad3 is still present for liver development.  The abnormality 
masking could arise because Smad2 heterozygote embryos either have enough TGF-β signaling 
to progress past AP specification/anterior development, or they succumb and resorb.  
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Considering how Smad2 functions similar to a coarse adjustment, Smad3 mutations might 
provide the fine adjustment to TGF-β signaling that introduces another threshold level of TGF-β 
signaling and reveals the synergism between Smad2 and Smad3 for liver development. 
These last two thresholds are likely the only ones remaining as far as Smad2/3-influenced 
thresholds are concerned since Smad23loxP/3loxP;Smad3+/- embryos were approximately 70% 
viable, so any abnormalities less severe than hepatic hypoplasia or HPE would be expected to 
manifest itself with embryos of this genotype.  To discern new functions, conditional knockouts 
will have to be utilized, or Smad2/3 mutations will have to be compounded with mutations in 
transcription factors, coactivators, or corepressors.  This avenue was investigated when the 
omnipotent p53 tumor suppressing protein was shown to be capable of binding with Smad2 and 
Smad3 to regulate transcriptional responses in the Xenopus model [31].  To investigate this 
interaction in the mouse model during embryogenesis, the fates of p53-/-;Smad2+/- pups and p53-/-
;Smad3-/- pups was investigated.  Pups of both genotypes were found to be viable with no 
unreported abnormalities over a course of a few months (data not shown), suggesting that, at 
least for embryogenesis, the interaction between p53 and Smad2 and Smad3 is insignificant. 
For future investigations, the suspected endodermal origin of the abnormalities observed 
in Smad23loxP/3loxP;Smad3+/- and Smad23loxP/3loxP;Smad3-/- should be confirmed via marker 
analysis.  In addition, investigation of the hepatic dysplasia observed in the Nodal mutants [30] 




Materials and Methods 
Mice and Genotype analysis 
In the above text, Smad2- refers to the Smad2∆C allele unless otherwise mentioned.  Mice 
were maintained on a mixed background of 129Svev and NIH Black Swiss.  Genotyping was 
performed via PCR analysis.  DNA samples from toe biopsies or yolk sacs were prepped by 
standard methods.  Detection of Smad23loxP and the Smad2 wild-type (WT) alleles both use 
primer 1 (5’-GAG CTG CGC AGA CCT TGT TAC-3’) and primer 2 (5’-TGC CTG ACA AAC 
AGT CCT GG-3’).  This primer pair flanks the first loxP site, resulting in an amplification 
product of ~350 bp for the WT allele and ~450 bp for the 3loxP allele.  Smad2∆E9,10 was detected 
using primer 1 and primer 3 (5’-GAA GGG GAT CCC ATC TGA GT-3’), which amplify 
fragment of ~850 bp [12].  The presence of Smad2∆C was visualized as ~150 bp fragment using 
primer 4 (5’-ACT TCG CTA GTT GCT CAT GG-3’) and primer 5 (5’-CCA CTT CAT TGC 
CAT ATG CCC TG-3’).  Smad3 WT allele was detected at ~400 bp using primer 5 and primer 6 
(5’-CCC GAA CAG TTG GAT TCA CAC A-3’).  The Smad3 null allele was detected at ~300 
bp with primer 5 and primer 7 (5’CCA GAC TGC CTT GGG AAA AGC-3’) [20].  WT p53 
alleles were genotyped using primer 7 (5'-ACA GCG TGG TGG TAC CTT AT-3') and primer 8 
(5'-TAT ACT CAG AGC CGG CCT-3'), which yielded ~450 bp fragments.  Mutant p53 allele 
was detected using primer 8 and primer 9 (5'-TCC TCG TGC TTT ACG GTA TC-3'), resulting 
in ~650 bp fragment after PCR analysis. 
 
Embryonic analyses 
Dissections were performed in 1X phosphate buffered saline in 0.1% Tween-20 (PBST) 
and the maternal tissues were dissected away from the embryo and its yolk sac.  The yolk sac 
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was digested to release DNA for genotype analysis, while the embryos were prepped according 
to the requirements of the subsequent procedure.  Pictures were taken with a MTI 3CCD digital 
camera attached to a Zeiss Stemi SVII Apo dissecting microscope and processed with Scion 
Series 7 software. 
 
Western Blot 
Protein was isolated from embryos that had been dissected according to the above 
procedure.  After cell lysis, Western blots were performed by running the samples on a 10% 
SDS-Page gel (Biorad), then transferred onto a Hybond™-ECL™ nitrocellulose membrane 
(Amersham) and probed with anti-Smad2/3 monoclonal IgG antibody (Transduction Labs) that 
recognizes Smad2 linker region/MH2 domain.  After washing, the blot was probed with anti-
mouse antibody coupled with alkaline phosphatase (Roche) and visualized using a 
chemiluminescence kit (Amersham) according to the manufacturer’s protocol [21]. 
 
Real-time PCR 
Embryonic tissues were lysed with by pipetting in Trizol (Invitrogen), and RNA was 
isolated according to standard procedures.  cDNA was replicated from RNA using Superscript III 
(Invitrogen) according to the manufacturer’s protocol.  Real-time PCR was prepped using Biorad 
iQ™ SYBR® Green Supermix for a total of 25 µL per PCR tube. The primers used for the real-
time PCR include primer 1 (5’-GAA GGG GAT CCC ATC TGA G-3’) and primer 2 (5’-CCC 
GAA TGT GCA CCA TAA G-3’), which amplify 150 bp fragment of cDNA from the distal end 
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Fig. 3.  Smad23loxP allele construction.  Modified from [12].
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Fig. 5.  Western Blot of Smad2 with α-tubulin control; note the decreased Smad2 protein concentration for 











Figure 6.  Breeding crosses of the P and F1 generations.  Except for Smad23loxP/3loxPSmad3-/- pups, all F2
genotype combinations were observed.






































E13.5 15 (0) 25 (8)
P21 42 (0) 57 (2)
9 (0)E9.5-E10.5
Table 1.  Genotypic analyses of litters resulting from intercrosses of  Smad23loxP/3loxPSmad3+/- mice. 
Numbers within parentheses denote number of abnormal embryos or mice.  Rsp stands for resorption, and 
P21 is short for postnatal day 21 ( the time of weaning).  p values are probabilities calculated from χ2
Smad23loxP/3loxP
Smad3+/- Smad3-/-
Axial Abnormality 0 3
Cardiac Dysplasia 4 6
Holoprosencephaly 2 0
Delayed Development 5 0
Resorption 1 0
Total number abnormal 12 8
Sample size 34 8
Percent Abnormal 35% 100%
Table 2.  E9.5-E10.5 embryo abnormalities
*abnormalities are not mutually exclusive*
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(D) E9.5 WT Embryo
(E) Milder Pericardial Effusion seen in a 
Smad23loxP/3loxPSmad3+/- mutant






Fig. 8.  (A) HPE with proboscis and hypotelorism (B) Severe anterior craniofacial truncation (C) Mild HPE 
with hepatic dysplasia (D) Hepatic dysplasia only (E) E13.5 WT







Hepatic Dysplasia 11 4
Holoprosencephaly 4 2
Anterior Craniofacial Truncation 1 1
Total Number Abnormal 13 4
Sample Size 49 4
Percent Abnormal 27% 100%
Table 3.  Abnormalities displayed by E12.5-E14.5 embryos.
*phenotypes not mutually exclusive*





















Fig. 9.  Levels of Smad2 and Smad3 required for viability; bars with total level of TGF-β signaling in the 
red zone are embryonically lethal, bars in the yellow zone exhibit a mixture of lethality and viability, and 
bars completely above the yellow zone are completely viable.  The approximate ratio of total Smad2 : total 




































































Table 4.  Levels of Smad2 and Smad3 required for viability
1 kb
Exon
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
Liu et al.
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11
1 2 3 4 5 6 7 8 9 10 11













1. Blobe, G.C., Schiemann, W.P., Lodish, H.F., Role of transforming growth factor β  in 
human disease. New England Journal of Medicine, 2000. 342: p. 1350-1358. 
2. ten Dijke, P., Hill, C.S., New insights into TGF-β–Smad signalling. TRENDS in 
Biochemical Sciences, 2004. 29(5): p. 265-273. 
3. Itoh, S., Itoh, F., Goumans, M.J., ten Dijke, P., Signaling of transforming growth factor-
beta family members through Smad proteins. Eur J Biochem., 2000. 267(24): p. 6954-
6967. 
4. Massague, J., TGFbeta signaling: receptors, transducers, and Mad proteins. Cell, 1996. 
85(7): p. 947-950. 
5. Hahn, S.A., Schutte, M., Hoque, A.T., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., 
Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H., Kern, S.E., DPC4, a candidate 
tumor suppressor gene at human chromosome 18q21.1. Science, 1996. 271(5247): p. 
350-353. 
6. Heldin, C.H., Miyazono, K., ten Dijke, P., TGF-beta signalling from cell membrane to 
nucleus through SMAD proteins. Nature, 1997. 390(6659): p. 465-471. 
7. Tian, F., DaCosta Byfield, S., Parks, W.T., Yoo, S., Felici, A., Tang, B., Piek, E., 
Wakefield, L.M., Roberts, A.B., Reduction in Smad2/3 signaling enhances tumorigenesis 
but suppresses metastasis of breast cancer cell lines. Cancer Res., 2003. 63(23): p. 8284-
8292. 
8. Han, S.U., Kim, H.T., Seong, D.H., Kim, Y.S., Park, Y.S., Bang, Y.J., Yang, H.K., Kim, 
S.J., Loss of the Smad3 expression increases susceptibility to tumorigenicity in human 
gastric cancer. Oncogene, 2004. 23(7): p. 1333-1341. 
9. Zhu, Y., Richardson, J.A., Parada, L.F., Graff, J.M., Smad3 mutant mice develop 
metastatic colorectal cancer. Cell, 1998. 94(6): p. 703-714. 
10. Nomura, M., Li, E., Smad2 role in mesoderm formation, left-right patterning and 
craniofacial development. Nature, 1998. 393(6687): p. 786-790. 
11. Weinstein, M., Yang, X., Li, C., Xu, X., Gotay, J., Deng, C.X., Failure of egg cylinder 
elongation and mesoderm induction in mouse embryos lacking the tumor suppressor 
smad2. Proc Natl Acad Sci U S A., 1998. 95(16): p. 9378-83. 
12. Liu, Y., Festing, M.H., Hester, M., Thompson, J.C., Weinstein, M., Generation of novel 
conditional and hypomorphic alleles of the Smad2 gene. Genesis, 2004. 40(2): p. 118-
123. 
13. Hamamoto, T., Beppu, H., Okada, H., Kawabata, M., Kitamura, T., Miyazono, K., Kato, 
M., Compound disruption of smad2 accelerates malignant progression of intestinal 
tumors in apc knockout mice. Cancer Res., 2002. 62(20): p. 5955-5961. 
14. Waldrip, W.R., Bikoff, E.K., Hoodless, P.A., Wrana, J.L., Robertson, E.J., Smad2 
signaling in extraembryonic tissues determines anterior-posterior polarity of the early 
mouse embryo. Cell, 1998. 92(6): p. 797-808. 
15. Heyer, J., Escalante-Alcalde, D., Lia, M., Boettinger, E., Edelmann, W., Stewart, C.L., 
Kucherlapati, R., Postgastrulation Smad2-deficient embryos show defects in embryo 
turning and anterior morphogenesis. Proc Natl Acad Sci U S A., 1999. 96(22): p. 12595-
12600. 
 23
16. Vincent, S.D., Dunn, N.R., Hayashi, S., Norris, D.P., Robertson, E.J., Cell fate decisions 
within the mouse organizer are governed by graded Nodal signals. Genes Dev., 2003. 
17(13): p. 1646-1662. 
17. Vivian, J.L., Chen, Y., Yee, D., Schneider, E., Magnuson, T., An allelic series of 
mutations in Smad2 and Smad4 identified in a genotype-based screen of N-ethyl-N- 
nitrosourea-mutagenized mouse embryonic stem cells. Proc Natl Acad Sci U S A., 2002. 
99(24): p. 15542-15547. 
18. Dunn, N.R., Koonce, C.H., Anderson, D.C., Islam, A., Bikoff, E.K., Robertson, E.J., 
Mice exclusively expressing the short isoform of Smad2 develop normally and are viable 
and fertile. Genes Dev., 2005. 19(1): p. 152-163. 
19. Datto, M.B., Frederick, J.P., Pan, L., Borton, A.J., Zhuang, Y., Wang, X.F., Targeted 
disruption of Smad3 reveals an essential role in transforming growth factor beta-
mediated signal transduction. Mol Cell Biol., 1999. 19(4): p. 2495-2504. 
20. Yang, X., Letterio, J.J., Lechleider, R.J., Chen, L., Hayman, R., Gu, H., Roberts, A.B., 
Deng, C., Targeted disruption of SMAD3 results in impaired mucosal immunity and 
diminished T cell responsiveness to TGF-beta. EMBO J., 1999. 18(5): p. 1280-1291. 
21. Liu, Y., Festing, M., Thompson, J.C., Hester, M., Rankin, S., El-Hodiri, H.M., Zorn, 
A.M., Weinstein, M., Smad2 and Smad3 coordinately regulate craniofacial and 
endodermal development. Dev Biol., 2004. 270(2): p. 411-426. 
22. Weinstein, M., Monga, S.P., Liu, Y, Brodie, S.G., Tang, Y., Li, C., Mishra, L., Deng, 
C.X., Smad proteins and hepatocyte growth factor control parallel regulatory pathways 
that converge on beta1-integrin to promote normal liver development. Mol Cell Biol., 
2001. 21(15): p. 5122-5131. 
23. Sauer, B., Inducible gene targeting in mice using the Cre/lox system. 1998, 1998. 14(4): 
p. 381-392. 
24. Bockamp, E., Maringer, M., Spangenberg, C., Fees, S., Fraser, S., Eshkind, L., Oesch, F., 
Zabel, B., Of mice and models: improved animal models for biomedical research. Physiol 
Genomics, 2002. 11(3): p. 115-132. 
25. Meyers, E.N., Lewandoski, M., Martin, G.R., An Fgf8 mutant allelic series generated by 
Cre- and Flp-mediated recombination. Nat Genet., 1998. 18(2): p. 136-141. 
26. Hester, M., Thompson, J.C., Mills, J., Liu, Y., El-Hodiri, H.M., Weinstein, M., Smad1 
and Smad8 function similarly in mammalian central nervous system development. Mol 
Cell Biol., 2005. 25(11): p. 4683-4692. 
27. Dunn, N.R., Vincent, S.D., Oxburgh, L., Robertson, E.J., Bikoff, E.K., Combinatorial 
activities of Smad2 and Smad3 regulate mesoderm formation and patterning in the mouse 
embryo. Development, 2004. 131(8): p. 1717-1728. 
28. Brennan, J., Norris, D.P., Robertson, E.J., Nodal activity in the node governs left-right 
asymmetry. Genes Dev., 2002. 16(18): p. 2339-2344. 
29. Norris, D.P., Brennan, J., Bikoff, E.K., Robertson, E.J., The Foxh1-dependent 
autoregulatory enhancer controls the level of Nodal signals in the mouse embryo. 
Development, 2002. 129(14): p. 3455-3468. 
30. Lowe, L.A., Yamada, S., Kuehn, M.R., Genetic dissection of nodal function in patterning 
the mouse embryo. Development, 2001. 128(10): p. 1831-1843. 
31. Cordenonsi, M., Dupont, S., Maretto, S., Insinga, A., Imbriano, C., Piccolo, S., Links 
between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating 
with Smads. Cell, 2003. 113(3): p. 301-314. 
 24
